Shares in psychedelic drug developer Compass Pathways are sliding today after it announced that it will slash its headcount by 30% and focus all its efforts on its treatment-resistant depre
After emerging from the shadows with a $100 million Series A in April, Seaport Therapeutics has moved swiftly to shore up its finances with a $225 million second round to fund the developme
All I wanted to do was die. If I could just clean out my gutters and “accidentally” fall off the roof, all of my problems would be solved. My misery would be over.
Otsuka has teamed up with one of the innovation arms of the NHS to explore how a digital therapeutic (DTx) for major depressive disorder (MDD) could be deployed within the health service.
Johnson & Johnson has filed for FDA approval of its antidepressant nasal spray Spravato, hoping to make it the first standalone treatment for adults with treatment-resistant depression
A mid-stage trial of oral ketamine tablets has shown promising results in treatment-resistant depression (TRD), setting up a phase 3 programme and a possible challenge to Johnson & John
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.